21-23 June 2010, Le Méridien Beach Plaza, Monte-Carlo, Monaco
The PharmaBrand Europe Summit 2010 will bring together senior-level executives from Europe's largest organisations with a select and diversified group of leading edge Solution Providers. Do not miss this opportunity to network with your peers and form new alliances. Get a head start on your competition and start building relationships today.
3rd Annual Pharmaceutical Pricing & Reimbursement in Central & Eastern Europe
Budapest, Hungary, June 7th-8th, 2010
This event will present the most updated and original perspectives on communicating the cost-effectiveness of high valued drugs to key stakeholders in the former communist countries of Central and Eastern Europe (CEE EU members, The Balkans, Russia and the former Soviet states).
There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increasing range of expensive drugs and technologies available as potential therapies.
Biosimilars: Key developments in the regulatory environment
This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. It also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.
Claim "10% Discount for Farmavita.Net Members" when purchasing this report!
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
This report provides a comprehensive examination of the clinical trial landscape in emerging countries, with specific focus on China, India, Central and Eastern Europe and Latin America. It identifies the major drivers and barriers to conducting clinical trials in emerging regions and profiles key issues for consideration when selecting a trial site.
Claim "10% Discount for Farmavita.Net Members" when purchasing this report!
Key Trends In Drug-diagnostic Co-development: Identifying collaborative opportunities and navigating regulatory challenges
This report explores the potential for applying genomic-based diagnostics to new drug developments, and the resultant implications for the pharma/biotech and diagnostic industries. It also reviews 28 collaborative agreements for the co-development of drug-diagnostics and determines which combinations can be expected to result in commercial products in the near future.
Claim "10% Discount for Farmavita.Net Members" when purchasing this report!
The exclusive Discovery Summit 2010 presents a unique opportunity to examine the challenges and advances in drug discovery. Within the luxurious surroundings of a five star venue, this networking event provides the perfect setting for discussion and knowledge sharing between the most prominent and innovative drug discovery leaders.
Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment
As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011.
The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.
New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
Global Pharmaceutical companies based in developed countries are increasingly turning to developing countries and emerging economies around the world for conducting clinical trials. Reduced costs combined with easy availability of patients with varied diseases makes developing countries favourite destinations for clinical research outsourcing.
The whole 9 pages article is available for download at Downloads section of FarmavitaR.com
Challenges in standardization in Traditional Medicine / Herbal Drugs
The use of herbs and herbal extracts to treat diseases has stood the test of time. Herbal products/traditional medicine are composed of many constituents and are, therefore, capable of variation. The variability of the plant material is due to different conditions of growth, harvesting, drying, and storage. The polarity of the solvent, the mode of extraction, and the instability of constituents may also influence the composition and quality of the extracts.
The whole 10 pages article is available for download at Downloads section of FarmavitaR.com.
Bosnia and Herzegovina-Act on Medical Products and Medical Devices
On May 1st 2009 the Agency for medical products and medical devices in Bosnia and Herzegovina has started with work. The Act on Medical Products and Medical Devices defines Agency's jurisdiction, how to apply for MA in Bosnia and Herzegovina, documentation for registration, pharmacovigilance, advertising...
The law is available for download at Downloads section of Farmavitar.Net. (in Bosnian!)
Variations to the terms of medicinal products registered in Albania
This file will explain you how to apply for variation to the trems of medical products and in short a procedure for revocation of marketing authorisation.
The whole 10 pages article is available for download at Downloads section of Farmavitar.Net
REGULATION FOR THE FOOD
SUPPLEMENTS REGISTRATION IN THE REPUBLIC OF ALBANIA
The Regulation for Food Supplements Registration
is implemented for the
food supplements which are introduced and marketed as alimentary products in the Republic of Albania.
FarmavitaR+ brings you a short description of the food supplements registration procedure.
The whole 8 pages article is available for download at Downloads section of Farmavitar.Net
THE ROLE OF INTELLECTUAL PROPERTY RIGHTS IN TRADITIONAL KNOWLEDGE: AN OVERVIEW
Intellectual properties (IP) are legal property rights over creations of the mind, both artistic and commercial, and the corresponding fields of law. Under intellectual property law, owners are granted certain exclusive rights to a variety of intangible assets, such as musical, literary, and artistic works; ideas, discoveries and inventions; and words, phrases, symbols, and designs.
The whole 4 pages article is available for download at Downloads section of Faramavitar.Net
FarmavitaR+ Journal 
